For decades, general health and science information has served as the foundation for public understanding of medical conditions and treatment options. This broad educational framework has empowered individuals to make informed decisions about their well-being, from preventive care to managing chronic diseases. Within this legacy, the dissemination of balanced, evidence-based knowledge has been paramount, ensuring that patients and healthcare providers alike can navigate complex therapeutic landscapes with clarity. As this heritage of health communication evolves, it naturally extends into more specialized domains where the intersection of medication use and patient safety demands focused attention. One such area involves the long-term administration of bisphosphonates, a class of drugs widely prescribed for bone density disorders. While these therapies have demonstrated significant benefits, their widespread use has prompted closer scrutiny of potential adverse outcomes in specific patient populations. This shift from general health education to targeted risk awareness reflects a necessary maturation in how medical information is contextualized.
Fosamax (alendronate) is a bisphosphonate medication prescribed to treat osteoporosis and other bone diseases. A known adverse effect associated with its use is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw. This section reviews the clinical presentation, pharmacological link, and risk considerations for patients in Pennsylvania who may be affected. Osteonecrosis of the jaw involves the death of bone tissue in the mandible or maxilla, often presenting as exposed bone that does not heal within eight weeks. The condition can occur spontaneously but is generally associated with dental procedures such as tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is based on clinical examination and imaging, with multiscale characterization of jawbone providing comprehensive information to help understand jawbone-specific responses to complications like bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077). Symptoms may include pain, swelling, numbness, or drainage in the jaw, and the time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
Fosamax works by inhibiting bone resorption, which helps increase bone density. However, this suppression of bone turnover can impair the jawbone's ability to repair microdamage and maintain blood supply. The mechanistic pathway linking Fosamax to ONJ involves reduced osteoclast activity, leading to compromised bone remodeling and increased susceptibility to infection and necrosis, particularly after dental trauma. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
The prescribing information for Fosamax includes a warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the adequacy of these warnings has been questioned, as some patients may not have been fully informed of the risk before starting treatment. In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may have contributed to underappreciation of the risk. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
The time to onset of ONJ symptoms can vary widely, from one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after stopping the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The incidence of ONJ is rare, with one study noting that atypical femoral fracture or osteonecrosis of jaw was uncommon and rare respectively (https://pubmed.ncbi.nlm.nih.gov/42046648). Fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years, after either three or five years of prescription (https://pubmed.ncbi.nlm.nih.gov/42046648). While ONJ is more commonly reported in human literature, it is also recognized in veterinary medicine, as highlighted by a retrospective case series on bisphosphonate-related ONJ in 20 cats (https://pubmed.ncbi.nlm.nih.gov/39247125).
For patients in Pennsylvania who have developed ONJ after using Fosamax, settlement considerations may include the adequacy of warnings provided by the manufacturer, the timing of diagnosis relative to drug exposure, and the severity of harm. Legal claims often focus on whether the manufacturer failed to adequately warn about the risk of ONJ, particularly given that the condition can occur spontaneously or after dental procedures. Patients should document their medical history, including the start and stop dates of Fosamax use, any dental procedures performed, and the onset of symptoms. The risk of ONJ may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), so patients who took Fosamax for extended periods may have stronger claims. Consulting with a legal professional experienced in pharmaceutical litigation can help affected individuals understand their options.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Fosamax (alendronate) is a bisphosphonate used to treat osteoporosis. It can cause osteonecrosis of the jaw (ONJ), a condition where jawbone tissue dies and becomes exposed. The risk is higher with dental procedures and long-term use. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)
Symptoms include pain, swelling, numbness, or drainage in the jaw, and exposed bone that does not heal within eight weeks. Onset can vary from one day to several months after starting Fosamax. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)
Diagnosis is based on clinical examination and imaging. Multiscale characterization of jawbone can help understand jawbone-specific responses to complications like bisphosphonate-related ONJ. (https://pubmed.ncbi.nlm.nih.gov/40345077)
Risk factors include invasive dental procedures, cancer, chemotherapy, corticosteroids, poor oral hygiene, periodontal disease, and longer duration of bisphosphonate use. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)
Yes, for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk of ONJ. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)
Patients should document their medical history, including Fosamax use dates, dental procedures, and symptom onset. Consulting a legal professional experienced in pharmaceutical litigation can help explore settlement options.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.